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Abstract
Background Vital tissue provided by fresh frozen tissue
banking is often required for genetic tumor profiling and
tailored therapies. However, the potential patient benefits
of fresh frozen tissue banking are currently limited to
university hospitals. The objective of the present pilot
study—the first one in the literature—was to evaluate
whether fresh frozen tissue banking is feasible in a regional
hospital without an integrated institute of pathology.
Methods Patients with resectable breast and colon cancer
were included in this prospective study. Both malignant
and healthy tissue were sampled using isopentan-based
snap-freezing 1 h after tumor resection and stored at
-80 C before transfer to the main tissue bank of a Uni-
versity institute of pathology.
Results The initial costs to set up tissue banking were
35,662 US$. Furthermore, the running costs are 1,250 US$
yearly. During the first 13 months, 43 samples (nine sam-
ples of breast cancer and 34 samples of colon cancer) were
collected from 41 patients. Based on the pathology reports,
there was no interference with standard histopathologic
analyses due to the sample collection.
Conclusions This is the first report in the literature pro-
viding evidence that tissue banking in a regional hospital
without an integrated institute of pathology is feasible. The
interesting findings of the present pilot study must be
confirmed by larger investigations.
Introduction
In the age of genetic tumor profiling and tailored therapies,
adequately preserved tissue for research purposes has
become mandatory. In this context, researchers are fre-
quently confronted with the limitations of formalin-
embedded tissue. In particular, proteomic analysis and
functional description of cells is reduced in these nonvital
specimens. Therefore, it is crucial to have access to vital
fresh frozen tissue for basic and translational research as a
growing body of scientific evidence demonstrates the
beneficial effect of the technique of gene expression pro-
filing with fresh frozen tissue of malignant tumors [1–6].
Since the late 1980s, there have been numerous reports on
various methods and strategies of tissue banking; and
especially over the last decade, networks for tissue banking
and specimen allocation were established in Europe and the
United States [7–11].
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All of these initiatives are run by and allocated in aca-
demic institutions with integrated institutes of pathology.
Therefore, the invaluable resource of tissue banking with
consequent unlimited possibilities regarding further diag-
nostic testing, more selective treatment, and potential
patient’s benefit are limited to academic institutions. This
is in sharp contrast to the fact that most cancer patients in
European countries are treated in nonacademic, middle-
sized regional hospitals. Hence, it is crucial that the enor-
mous benefits of fresh tissue banking are not limited
exclusively to large academic institutions.
Therefore, the objective of the present pilot study—the
first one in the literature—was to evaluate whether tissue
banking is feasible in a regional hospital without an inte-
grated institute of pathology.
Patients and methods
The study was performed in a Swiss regional hospital
(approximately 11,500 inpatients per annum, 2,000 of
whom are surgical inpatients) in collaboration with the
Institute of Pathology at the University of Basel (Basel,
Switzerland). The two hospitals are located approximately
38 miles from each other. The study outline was submitted
to and approved by the joint Ethics Committee of the
Canton Aargau and Solothurn in 2008.
A process of stepwise consent for specimen collection,
specimen storage, and subsequent utilization for research
purposes was implemented with the explicit possibility of
revocation of the consent at any time by the patient.
Patients were eligible for the study if they were
C18 years, had a proven resectable cancer of the breast or
colon, and were scheduled for a surgical intervention to
remove the malignancy. Moreover, the minimum tumor
size was set at 1 cm in diameter. Patients with tumors
\1 cm in diameter or patients with rectal cancer were not
included in the present study to avoid potential interference
with standard histopathologic analyses. During the stan-
dard patient education for consent during the preoperative
outpatient visit about a week prior to the operation; eligible
patients were informed about the possibility of fresh frozen
tissue banking and its risks. Information and consent forms
were handed out in advance. During the second patient
encounter the day before surgery, remaining concerns and
questions were clarified, and the consent form was signed
by the patient.
An instructed surgical resident collected the samples
within 1 h after tumor resection. Samples were collected
from both the tumor and the surrounding healthy tissue,
each sample being 3–5 mm in diameter. During the first
five resections, a certified pathologist was present to train
three exclusive surgical residents and to monitor the tissue
sampling. The residents were carefully instructed about
handling the resected colon and breast cancer tissues. The
resected tumor specimens were macroscopically reviewed.
Threads were used to mark the orientation of the specimen.
Important areas for pathologic staging, such as resection
margins, were left untouched—for later analysis by an
experienced pathologist. Pathologists were present for all
sentinel lymph node examinations for breast cancer
patients. They also supervised and monitored the specimen
collection during tumorectomies, which were carried out
by the instructed residents.
Both samples (cancerous and healthy tissue) were pre-
pared for deep freezing with 5 ml of embedding solution
(Tissue-Tek O.C.T.; Medite Medizintechnik AG, Nunnin-
gen, Switzerland) in a plastic tray. Freezing was performed
using an Isopentan shock freezer (SnapFrost80; Medite
Medizintechnik AG) in a special area in the operating
theater and took 1–2 min. Samples were then placed into
small polyvinyl chloride bags, labeled, coded (alphanu-
meric code), and stored at -80 C (Frykavision, -80 C
deep freezer; MultiTemp Scientific AG, Urdorf, Switzer-
land). Every 6 months the collected samples were trans-
ferred on carbon dioxide snow to the Institute of Pathology
at the University of Basel.
Data were recorded prospectively, including the
patient’s age, sex, primary diagnosis, co-morbidities, TNM
staging and grading, carcinoembryonic antigen (CEA) titer
(in those with colon cancer), and the patients medications
at the time of sample collection. The standard histopatho-
logic reports were reviewed for potential interference with
the sample collection. In case of suspected interference, a
review of the frozen tissue samples would have been
possible. However, this issue never occurred during the
present pilot study.
Follow-up data included type of adjuvant treatment,
surgical and nonsurgical complications, date of recurrence,
and date of death. The data were reversibly anonymized.
Project investment and running costs were prospectively
monitored, and the costs per sample were calculated.
Results
The age of the patients at time of sampling ranged from 55
to 88 years (median 77.5 years). Overall, tissue of 16 men
and 16 women with diagnosed colon malignancies or high-
grade dysplastic lesions and nine women with diagnosed
breast cancer were sampled.
The median number of co-morbidities was 2 with a
range from 0 to 6. In all, 16 patients (16/41; 39 % of all
patients) had only one or no co-morbid condition.
During the first 13 months, 43 samples were collected
from 41 patients. Overall, 45 patients were operated on
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over the pilot study period due to malignancies of the colon
and breast. Three colon tumors failed to be collected in the
context of emergency operations and one breast cancer due
to human failure. Consequently, 91 % of the patients were
correctly sampled (41/45).
Altogether, nine samples of breast tumors and 34 sam-
ples of colon tumors were collected. All breast cancer
patients were operated on including a sentinel lymph node
procedure. A total of 12 sigmoid carcinomas, 18 carcino-
mas of the right hemicolon (including two double carci-
nomas), and four nonmalignant lesions (one pseudotumor
in a patient with chronic diverticulitis and three tubulo-
villous adenomas) were detected on pathologic analysis.
In the breast cancer group, there were five pT1c and four
pT2 tumors. In the colon cancer group, there was one pT1,
nine pT2, 18 pT3, and four pT4 tumors, resulting in UICC
stage distribution of seven patients with stage I, and ten,
eight, and three patients with stage II, III, and IV, respec-
tively [12].
Three patients in the breast cancer group had one or
more positive axillary lymph nodes (after sentinel lymph
node biopsy, frozen section, and consecutive axillary
lymph node dissection), but no patient had known distant
metastatic disease at the time of operation (although two
were found to have metastases after postoperative restag-
ing). Three patients in the colon cancer group had known
metastatic disease at the time of operation, and another was
found to have metastases after resection.
In the colon cancer group, 19 patients underwent adju-
vant chemotherapy. Seven of nine breast cancer patients
were treated with radiation to the remaining breast after
tumorectomy and three of these seven patients with addi-
tional radiation to the axilla (pN3a). The other four
were lymph node-negative on sentinel lymph node biopsy
(pN0), and radiotherapy was given routinely after breast-
conserving treatment. Eight of nine breast cancer patients
received adjuvant chemotherapy and/or hormone therapy.
During this pilot study we received systematic feedback
from our collaborating pathologists, who confirmed that all
specimens, which they received after tissue for fresh frozen
banking was removed, were in no way compromised
regarding standard histopathology analyses.
The median follow-up time was 610 days (range
10–840 days). It included one patient with colon cancer,
who died because of cardiac failure on postoperative day
10. Up to April 2011, no patient was lost to follow-up; nine
patients had died, six of whom had no proven cancer
recurrence. Three patients died with metastatic disease
(two colon cancer patients with lung and liver metastasis,
one breast cancer patient with bone metastases).
The total initial costs for tissue banking amounted
to 35,662 US$ (CHF 38,757) (Table 1) [13]. Of these
costs, 27,249 US$ (CHF 29,614) was spent for the
isopentan-based shock froster, 8,413 US$ (CHF 9,143) for
a -80 C deep freezer, and 1,250 US$ (CHF 1,358.50) was
invested in utility material including isopentan, Tissue-
Tek, plastic bags, labeling material, electricity, and trans-
portation costs during the first year (Tables 1, 2). To cal-
culate the cost per sample, we approximated 45 samples/
annum over a period of 10 years, which resulted in a mean
cost of 108 US$/sample (118 CHF/sample) (Table 2).
Discussion
To our knowledge, this pilot study is the first report in the
literature of fresh frozen tissue banking in a hospital
without an integrated institute of pathology. This attempt
was initiated by surgical oncologists and proved to be
successful.
During the last three decades biobanking and especially
fresh frozen tissue banking has been a domain almost
exclusively reserved to pathologists. There are numerous
reports about successful fresh frozen tissue banks that are
run by institutes of pathology in academic centers [7–9,
14–16]. Collaborative networks of these institutions have
been founded since the 1990s, such as the Cooperative
Human Tissue Network (CHTN) run by the National
Cancer Institute in the United States, or the TuBaFrost
initiative connecting large local European fresh frozen
tissue collections in academic institutions in Spain, The
Netherlands, Belgium, United Kingdom, Austria, and
France [9, 10].
Table 1 Initial and running and costs for tissue banking at a regional
hospital
Acquisition Cost
(US$)
Initial purchases
SnapFrost isopentan shock freezer 27,249
Frykavision -80  deep freezer 8,413
Total 35,662
Total running costs per annum
Labeling of specimens 35
PVC specimen bags 117
Methylbutane for snap freezing (100.75 US$/L) 9 5 504
Kryostat O.C.T. embedding solution (94.31 US$/
125 ml) 9 2
189
Electricity (300 kwh/a) 55
Transportation (29/a, 76 miles) 166
Dry ice for transportation (2 9/a) 184
Total 1,250
Total running costs ? investment (during first year) 36,912
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One major advantage of fresh frozen tissue banking in a
midsized regional hospital is the composition of the study
population. Academic centers tend to treat a negative
selection of patients in poor condition with multiple co-
morbidities and advanced-stage disease. This may lead to a
relevant selection bias, which can dramatically affect
research findings [17–19]. Patients in our study population
varied in age and tumor localization but tended to be less
affected by multiple co-morbid diseases: 39 % of all
patients had only one or no comorbid condition. The dis-
tribution of tumor localization and the T stage were similar
to the findings of important epidemiologic studies from
cancer registries [20–22].
The present pilot study demonstrates that tissue banking
in a regional hospital is feasible, although it comes with a
price. Even considering the fact that the freezing and
storage devices can be used over a period of 10 years, the
costs for one individual sample are high (approximating 45
samples/annum over a period of 10 years would result in
108 US$/sample (118 CHF/sample). In contrast, the
amount chargeable to public insurance in Switzerland for a
standard histopathologic analysis of a colorectal cancer
sample is only 126 US$ (136.50 CHF) [23]. It seems
obvious that additional public and/or private funding is
mandatory to be able to offer this auxiliary service.
In the present study, specimen collection by surgical
oncologists was safe. However, to achieve this goal we
limited eligible tumors to breast and colon cancer only in
the present pilot study. For patients with rectal cancer, we
considered the risk of interference with standard
histopathologic analyses too high because of the impor-
tance of proper assessment of the circumferential resection
margin in patients undergoing total mesorectal excision
[24]. However, we intend, in collaboration with a certified
pathologist, to expand the spectrum of malignant diseases
to be collected in the future to gastric and pancreatic
cancer. For these types of cancer, it is key that a board-
certified pathologist or well-trained resident performs the
fresh tissue sampling as it is of prime importance to avoid
compromising the quality of the specimens for standard
histopathologic analyses.
One area of conflict concerning specimen collection for
research purposes by nonpathology residents might be
medicolegal concerns. However, the study was approved
by the ethics committee of our medical center. Second, the
specimen collection was done by pathologist-trained resi-
dents, and the quality of our tissue collection was regularly
scrutinized by our collaborating pathologists. Third, all
patients gave written and verbal informed consent regard-
ing participating in this pilot study. Finally, although it
would be interesting to analyze the removed fresh frozen
tissue to ensure high quality, it was beyond the scope of the
present pilot study.
Conclusions
This is the first report in the literature that has provided
evidence that tissue banking in a regional hospital without
an integrated institute of pathology is feasible. However,
Table 2 Approximate costs per sample after 1–10 years (including investment and running costs) under the assumption of processing 45
samples per annum
Parameter DY 1 DY 2 DY 3 DY 4 DY 5 DY 6 DY 7 DY 8 DY 9 DY 10
Major costs
Med. Tech.
30 %
$10,698.60 $7,489.02 $5,242.31 $3,669.62 $2,568.73 $1,798.11 $1,258.68 $881.08 $616.75 $431.73
Book value
31.12.
$24,963.40 $17,474.38 $12,232.07 $8,562.45 $5,993.71 $4,195.60 $2,936.92 $2,055.84 $1,439.09 $1,007.36
Imputed
interest 5 %
$534.93 $374.45 $262.12 $183.48 $128.44 $89.91 $62.93 $44.05 $30.84 $21.59
Utility
materials
(Table 1)
$1,250.00 $1,250.00 $1,250.00 $1,250.00 $1,250.00 $1,250.00 $1,250.00 $1,250.00 $1,250.00 $1,250.00
Total $12,483.53 $9,113.47 $6,754.43 $5,103.10 $3,947.17 $3,138.02 $2,571.61 $2,175.13 $1,897.59 $1,703.31
Costs per
sample
(45/annum)
$277.41 $202.52 $150.10 $113.40 $87.71 $69.73 $57.15 $48.34 $42.17 $37.85
Average cost
per sample
over 10 years
$108.64
DY depreciation year
Med Tech 30 %: depreciation of 30 % on book value at the beginning of the year, Book value 31.12.: book value at the end of the year, Imputed
interest 5 %: imputed interest on the yearly depreciation with a rate of 5 %
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private or public funding is mandatory to perform fresh
frozen tissue banking at a regional hospital. The interesting
findings of the present pilot study must be corroborated by
larger investigations.
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